On December 10, 2025 NuCana plc (NASDAQ: NCNA) ("NuCana" or the "Company") reported the latest clinical data at the annual European Society for Medical Oncology ("ESMO") Immuno-Oncology Congress, December 10-12, 2025, in London.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The data from patients with PD-1 inhibitor-resistant metastatic melanoma treated with NUC-7738 in combination with pembrolizumab continue to demonstrate clinical activity and a favorable safety profile. All patients had progressive disease prior to starting treatment. Clinical activity includes two partial responses (one confirmed) and seven cases of stable disease, notably including one ongoing stable disease converting to a complete metabolic response with no detectable active disease. These results further reinforce the initial findings presented at the ESMO (Free ESMO Whitepaper) Congress 2024.

As of the most recent analysis, nine patients have been treated in the Expansion Cohort, which is part of the planned enrollment of up to 28 additional patients. Combined with the 12 patients previously treated in the Dose Confirmation Cohort, this will provide a total combination dataset comprising up to 40 patients. No new safety signals have been observed, and several patients remain on therapy with ongoing disease control, including one unconfirmed partial response and durable stable disease.

"We are very pleased to share the continued progress from this study," said Hugh S. Griffith, NuCana’s Founder and Chief Executive Officer. "The clinical activity and favorable safety profile of NUC-7738 support its potential to offer meaningful benefit for patients with advanced melanoma who have exhausted current treatment options."

Mr. Griffith added: "These findings support continued enrollment and further clinical advancement as we move toward a potential registrational pathway."

One of the study participants, who achieved complete metabolic response, was recently featured in the UK Channel 4 documentary series Cancer Detectives: Finding the Cures, which also profiled Professor Sarah Blagden, the study’s lead investigator and Professor of Experimental Oncology at the University of Oxford.

Details of NuCana’s presentation at the ESMO (Free ESMO Whitepaper) Immuno-Oncology Congress 2025 are as follows:

Abstract Title: A Phase 2 expansion study of NUC-7738 in combination with pembrolizumab in patients with PD-1 inhibitor-resistant cutaneous melanoma (NuTide:701)

Poster Number: 321TiP

Date: Wednesday, December 10, 2025

Presenting Author: Dr Miranda J. Payne

All regular abstracts accepted for presentation at the ESMO (Free ESMO Whitepaper) Immuno-Oncology Congress 2025 have been published online via the ESMO (Free ESMO Whitepaper) website on Thursday, December 4 at 12:05 p.m. CET (Wednesday, December 3 at 6:05 p.m. ET). All accepted abstracts will be published online in the ESMO (Free ESMO Whitepaper) Immuno-Oncology Congress 2025 Abstract Book, a supplement to the official ESMO (Free ESMO Whitepaper) journal, Immuno-Oncology and Technology (IOTECH).

More information regarding the 2025 ESMO (Free ESMO Whitepaper) Immuno-Oncology Congress can be found at: View Source

(Press release, Nucana, DEC 10, 2025, View Source [SID1234661349])